A5062769367- Monoclonal and Polyclonal Antibodies Research
- Animal Virus Infections Studies
- SARS-CoV-2 and COVID-19 Research
- HER2/EGFR in Cancer Research
- COVID-19 Clinical Research Studies
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Shanghai Institute of Materia Medica
2020-2022
Chinese Academy of Sciences
2020-2022
University of Chinese Academy of Sciences
2020-2022
Abstract The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351, B.1.617.1, P.1), SARS-CoV HCoV-NL63, without markedly affecting physiological...
Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), well other cancers (BCs). This study aims to investigate the biomarker value TROP2 patient-tailoring and prognostic BC patients, including TNBC.The levels expression in 404 Chinese tissues on tissue microarrays (TMAs) were quantified by immunohistochemistry their correlations clinicopathological factors overall survival rate analyzed. Also,...
Abstract The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351, B.1.617.1 P.1), SARS-CoV HCoV-NL63, without markedly affecting physiological...